Boundless Bio, Inc.
NASDAQ: BOLD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zachary Hornby
- Employees
- 64
- Headquarters
- San Diego, United States
- IPO year
- 2016
- Market cap
- $32.1M
- Website
- https://boundlessbio.com
Loading BOLD…
Loading profile data…Frequently asked questions about BOLD
What does Boundless Bio, Inc. (BOLD) do?
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor...
Where does BOLD trade?
Boundless Bio, Inc. (BOLD) trades on the NASDAQ Global Select.
What sector is BOLD in?
Boundless Bio, Inc. (BOLD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Boundless Bio, Inc.?
Zachary Hornby is the chief executive officer of Boundless Bio, Inc. (BOLD).
Where is Boundless Bio, Inc. headquartered?
Boundless Bio, Inc. is headquartered in United States.
Does BOLD pay a dividend?
Boundless Bio, Inc. (BOLD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BOLD go public?
Boundless Bio, Inc. (BOLD) completed its initial public offering in 2016.